Abstract

Background:
Camel milk has been widely investigated for its therapeutic potential, particularly its immunomodulatory and anti-inflammatory properties; however, information regarding its systemic safety under allergic inflammatory conditions remains limited.

Aim:
This study evaluated the systemic safety of camel milk administration in an ovalbumin (OVA)-induced allergic Wistar rat model.

Methods:
Twenty-five male Wistar rats (8–10 weeks old) were randomly allocated into five groups (n = 5): negative control, prophylactic camel milk, OVA-induced allergic control, therapeutic camel milk, and prednisolone-treated reference group. Allergic inflammation was induced through intraperitoneal sensitization and challenge with OVA. Camel milk (10 mL/kg/day) was administered orally under prophylactic and therapeutic regimens, while prednisolone (5 mg/kg/day) served as a pharmacological reference treatment. Body weight progression was monitored throughout the experimental period, and hematological parameters together with serum alanine aminotransferase, aspartate aminotransferase, urea, and creatinine levels were evaluated at the endpoint.

Results:
All groups demonstrated progressive physiological weight gain without evidence of treatment-related growth suppression. The OVA group exhibited leukocytosis, neutrophilia, and eosinophilia, confirming systemic inflammatory activation, whereas camel milk–treated groups showed moderated leukocyte responses with eosinophil levels approaching physiological ranges. Red blood cell indices, platelet counts, and liver and renal function markers remained within normal physiological limits.

Conclusion:
These findings indicate that oral camel milk administration is systemically well tolerated in OVA-induced allergic Wistar rats and supports its physiological safety as a complementary dietary intervention under allergic conditions.

Key words: Allergy; Camel milk; Ovalbumin model; Serum biochemistry; Wistar rats.